Enoximone
From Wikipedia, the free encyclopedia
 |
|
|
Enoximone
|
|
| Systematic (IUPAC) name | |
| 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3- dihydroimidazol-2-one |
|
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| Chemical data | |
| Formula | C12H12N2O2S |
| Mol. mass | 248.302 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 50% (oral) |
| Protein binding | 85% |
| Metabolism | Hepatic oxidation |
| Half life | 4 to 10 hours |
| Excretion | Renal (60 to 70%) |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Enoximone (INN, trade name Perfan®) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
|
|
|
|---|---|
| PDE1 | Vinpocetine |
| PDE2 | EHNA |
| PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
| PDE4 | Mesembrine, Rolipram |
| PDE5 | Sildenafil, Tadalafil, Vardenafil |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
